Antibodies, Neoplasm

"Antibodies, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.

Descriptor ID	D000912
MeSH Number(s)	D12.776.124.486.485.114.240 D12.776.124.790.651.114.240 D12.776.377.715.548.114.240
Concept/Terms	Antibodies, Neoplasm Antibodies, Neoplasm Neoplasm Antibodies Tumor Antibodies Tumor Antibodies Antibodies, Tumor

Below are MeSH descriptors whose meaning is more general than "Antibodies, Neoplasm".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Neoplasm [D12.776.124.486.485.114.240]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Neoplasm [D12.776.124.790.651.114.240]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Neoplasm [D12.776.377.715.548.114.240]

Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neoplasm".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antibodies, Neoplasm" by people in this website by year, and whether "Antibodies, Neoplasm" was a major or minor topic of these publications.

Bar chart showing 17 publications over 12 distinct years, with a maximum of 3 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	1	0	1
1998	1	0	1
2002	1	1	2
2003	1	1	2
2004	0	1	1
2007	1	1	2
2008	1	0	1
2009	1	2	3
2015	1	0	1
2016	1	0	1
2019	1	0	1

Below are the most recent publications written about "Antibodies, Neoplasm" by people in Profiles.

Weitzenfeld P, Bournazos S, Ravetch JV. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. J Clin Invest. 2019 09 03; 129(9):3952-3962.

View in: PubMed
Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, ?stling J, Dahan R, Harris RA, Rantalainen M, Klevebring D, Sund M, Brage SE, Fuxe J, Rolny C, Li F, Ravetch JV, Karlsson MC. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Rep. 2016 05 31; 15(9):2000-11.

View in: PubMed
DiLillo DJ, Ravetch JV. Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunol Res. 2015 Jul; 3(7):704-13.

View in: PubMed
Ekdawi NS, Pulido JS, Itty S, Marler RJ, Herman DC, Hardwig P, Mohney BG, Valyi-Nagy T, Shukla D. Intravitreal alemtuzumab penetrates full-thickness retina in rabbit eyes. Retina. 2009 Nov-Dec; 29(10):1532-4.

View in: PubMed
Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.

View in: PubMed
Hayes DF, Cristofanilli M. Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009 Jun 16; 101(12):894-5; author reply 896-7.

View in: PubMed
Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol. 2008 May 01; 180(9):6392-401.

View in: PubMed
Wang Y, Ylera F, Boston M, Kang SG, Kutok JL, Klein-Szanto AJ, Junghans RP. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Res Treat. 2007 Aug; 104(2):129-44.

View in: PubMed
Eisen HJ. Immunosuppression on the horizon. Heart Fail Clin. 2007 Jan; 3(1):43-9.

View in: PubMed
Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R, Wikstrand CJ, Bigner D, DeMichele A, Acs G, Berlin JA, Herlyn D. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol. 2004 Nov 15; 173(10):6472-80.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement